Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGIXNASDAQ:ENVBNASDAQ:PPBTNASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGIXCancer Genetics$0.19$0.26$2.11▼$17.50$792K2.722.44 million shs19,116 shsENVBEnveric Biosciences$1.23+1.2%$1.47$1.01▼$15.45$3.03M0.68734,887 shs25,004 shsPPBTPurple Biotech$2.24$2.64$2.00▼$20.60$2.98M0.57269,560 shs67,991 shsSPRBSpruce Biosciences$0.07+2.8%$0.24$0.06▼$0.87$3.08M2.49738,716 shs544,976 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGIXCancer Genetics0.00%0.00%0.00%0.00%0.00%ENVBEnveric Biosciences-6.59%-11.40%-0.41%-30.35%-91.27%PPBTPurple Biotech-8.94%-11.46%-13.18%-32.12%+223,999,900.00%SPRBSpruce Biosciences-1.39%-14.48%-74.73%-82.18%-90.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGIXCancer GeneticsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences1.8514 of 5 stars3.53.00.00.00.60.01.3PPBTPurple Biotech2.6656 of 5 stars3.55.00.00.02.70.00.6SPRBSpruce Biosciences2.1291 of 5 stars3.03.00.00.01.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGIXCancer Genetics 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00716.33% UpsidePPBTPurple Biotech 3.00Buy$33.001,373.21% UpsideSPRBSpruce Biosciences 2.00Hold$2.172,872.11% UpsideCurrent Analyst Ratings BreakdownLatest CGIX, SPRB, PPBT, and ENVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$1.50 ➝ $0.503/6/2025ENVBEnveric BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGIXCancer Genetics$6.33M0.13N/AN/AN/A∞ENVBEnveric BiosciencesN/AN/AN/AN/A$10.71 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$27.18 per shareN/ASPRBSpruce Biosciences$4.91M0.63N/AN/A$1.88 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGIXCancer GeneticsN/A-$2.07N/A∞N/AN/AN/AN/AN/AENVBEnveric Biosciences-$17.29M-$38.38N/AN/AN/AN/A-221.54%-164.32%5/13/2025 (Estimated)PPBTPurple Biotech-$19.88M-$5.25N/AN/AN/AN/A-55.86%-44.67%5/20/2025 (Estimated)SPRBSpruce Biosciences-$47.92M-$1.28N/AN/AN/A-555.23%-62.10%-47.49%5/12/2025 (Estimated)Latest CGIX, SPRB, PPBT, and ENVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AENVBEnveric Biosciences-$3.45N/AN/AN/AN/AN/A5/12/2025Q4 2024SPRBSpruce Biosciences-$0.20N/AN/AN/A$0.89 millionN/A4/15/2025Q4 2024SPRBSpruce Biosciences-$0.20-$0.57-$0.37-$0.57$0.50 million$0.55 million3/10/2025Q4 2024PPBTPurple Biotech-$0.22-$0.26-$0.04-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGIXCancer GeneticsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGIXCancer GeneticsN/AN/AN/AENVBEnveric BiosciencesN/A5.175.17PPBTPurple BiotechN/A1.271.27SPRBSpruce Biosciences0.015.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGIXCancer Genetics8.92%ENVBEnveric Biosciences13.82%PPBTPurple Biotech9.64%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipCGIXCancer Genetics15.00%ENVBEnveric Biosciences3.20%PPBTPurple Biotech2.98%SPRBSpruce Biosciences9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGIXCancer GeneticsN/A4.09 millionN/ANot OptionableENVBEnveric Biosciences202.47 million656,000Not OptionablePPBTPurple Biotech201.33 million1.29 millionOptionableSPRBSpruce Biosciences2042.23 million37.54 millionOptionableCGIX, SPRB, PPBT, and ENVB HeadlinesRecent News About These CompaniesSpruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacksMay 7 at 11:27 PM | investing.comSpruce Biosciences Inc Ordinary SharesMay 6 at 7:40 PM | morningstar.comSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 6 at 7:40 PM | finance.yahoo.comQ1 EPS Estimate for Spruce Biosciences Reduced by AnalystMay 3, 2025 | americanbankingnews.comSpruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease AssetApril 28, 2025 | biospace.comSpruce halves head count, narrowing focus to get ex-BioMarin drug to FDAApril 28, 2025 | fiercebiotech.comSpruce Biosciences (SPRB) Receives a Hold from RBC CapitalApril 17, 2025 | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call TranscriptApril 17, 2025 | insidermonkey.comSpruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)April 15, 2025 | standard-journal.comWith BioMarin deal, Spruce Biosciences hits reset on rare-disease drugApril 15, 2025 | bizjournals.comSpruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)April 15, 2025 | seekingalpha.comSpruce Biosciences reports delayed annual filingApril 3, 2025 | investing.comSpruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying ValueFebruary 5, 2025 | bovnews.comHold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic UncertaintiesDecember 16, 2024 | markets.businessinsider.comSpruce Biosciences (SPRB) Upgraded to Buy: Here's WhyDecember 13, 2024 | zacks.comJMP Securities Downgrades Spruce Biosciences (SPRB)December 12, 2024 | msn.comSpruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubtDecember 11, 2024 | fiercebiotech.comSpruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic ReevaluationDecember 11, 2024 | markets.businessinsider.comWhat’s Driving Spruce Biosciences Inc (SPRB) Stock’s 0.22% Surge Over the Past Month?December 11, 2024 | bovnews.comOppenheimer Downgrades Spruce Biosciences (SPRB)December 11, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGIX, SPRB, PPBT, and ENVB Company DescriptionsCancer Genetics NASDAQ:CGIXVyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.Enveric Biosciences NASDAQ:ENVB$1.23 +0.02 (+1.24%) Closing price 03:59 PM EasternExtended Trading$1.22 -0.01 (-0.41%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Purple Biotech NASDAQ:PPBT$2.24 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.03 (+1.56%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Spruce Biosciences NASDAQ:SPRB$0.07 +0.00 (+2.82%) As of 03:59 PM EasternSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
